$NTRA News

Last published 1d ago

1d agoNTRA INCYNatera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal CancerBusiness WireAUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC). The trial will evaluate INCA33890, Incyte’s investigational bispecific immunotherapy, in patients with stage 2/3 CRC who have co ...
2d agoNTRAUBS Global Healthcare Conference - NATERA INCEarnings Call TranscriptsAll right. Good morning, everybody. Thank you for joining us. On behalf of UBS, well, first off, I'm Doug Schenkel, just in case you don't know. And it's my pleasure on behalf of UVS to welcome Mike Brophy, CFO of Natera
6d agoNTRANatera, Inc. Q3 2026 Earnings Conference Call - NATERA INCEarnings Call TranscriptsHello, everyone. Thank you for joining us, and welcome to Natera's second quarter 2026 Earnings Conference Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a ques
6d agoNTRANatera, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoNTRANatera to Report its Third Quarter Results on November 5, 2026Business WireNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2026, after the market closes on November 5,
2w agoNTRASignatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder CancerBusiness WireNatera’s oncology portfolio featured in 25 ESMO abstracts including 9 oral presentations, with publications in Nature Medicine and ESMO Open Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision
2w agoNTRANatera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™Business WireAnalyses drawn from a large real-world database of patients underscore how genetic testing can support better care in chronic kidney disease (CKD) Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and
3w agoNTRAESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD TechnologyBusiness WireNatera and its collaborators will present 20 abstracts, including 4 rapid oral presentationsSignatera™ Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of
3w agoNTRANatera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026Business WireSignatera recognized in the Medical & Healthcare category for its transformative impact on cancer care Natera also named to Fortune’s Future 120, which highlights companies poised to define the next chapter of
4w agoNTRA RNAZNatera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal CancerBusiness WireTransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc.
1mo agoNTRAFDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection AssayBusiness WireDesignation supports the development of a blood-based assay intended to screen for various cancers Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that its
1mo agoNTRANatera Announces Randomized, Signatera™-Guided Interventional Study in MelanomaBusiness WireFirst patients enrolled in multi-center trial evaluating MRD-guided escalation for patients with advanced melanoma Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced
1mo agoNTRANew Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation OncologistsBusiness WireFour oral presentations spanning gastrointestinal and gynecologic cancers demonstrated Signatera’s role in informing personalized care management, including radiotherapy treatments Natera, Inc. (NASDAQ:NTRA), a
1mo agoNTRAAlliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast CancerBusiness WireTrial will use Natera’s ultrasensitive MRD test, Signatera Genome with Phased and Structural Variants, paired with giredestrant monotherapy, Genentech’s investigational oral SERD, aiming to spare patients unnecessary
1mo agoNTRASignatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder CancerBusiness WireSecond PMDA approval for Signatera in three months and first PMDA-approved CDx in MRD-guided care; commercial launch expected in 1H’27, pending final reimbursement and pricing Natera, Inc. (NASDAQ:NTRA), a global
1mo agoNTRALargest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTMBusiness WireData on >1,100 patients presented at the World Conference on Lung Cancer shows Signatera MRD status strongly predicted recurrence-free and overall survival in resected non-small cell lung cancer, with findings
1mo agoNTRABAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - NATERA INCEarnings Call TranscriptsGood afternoon, everyone. Thanks for joining us. My name is Robbie Bamberger, Senior Research Analyst, Life Science List, and Diagnostics at Baird. I'm pleased to have Mike Brophy, CFO here with us. Yeah, I guess before
1mo agoNTRANatera, Inc - 1773798 - NATERA INCEarnings Call TranscriptsOkay, I know we're a couple of minutes away, but I think we can get started, given there's a lot to cover. I'm Callum Tischmast, the Life Sciences Analyst here at Morgan Stanley. I'm really pleased today to be joined by
2mo agoNTRANew Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in LymphomaBusiness WireSignatera demonstrates 100% positive predictive value for treatment response assessment, detects recurrence months earlier than imaging, and supports precise, individualized lymphoma management through serial ctDNA
2mo agoNTRANatera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast CancerBusiness WireThe partnership combines Natera's leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen's global advocacy and patient support network Natera, Inc.
2mo agoNTRANatera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™Business WireNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of
3mo agoNTRANatera CG 46th Annual Growth Conference - NATERA INCEarnings Call TranscriptsHi, welcome to the Canaccord Genuity Growth Conference. I'm Kyle Mixon. I cover lifestyle and tools and diagnostics with Canaccord. Pleased to have Natera here with us for a first-time chat. With the company, we have Mik
3mo agoNTRANatera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin CancersBusiness WirePhase I trial in Germany will support treatment response monitoring for Kupando Therapeutics’ investigational immunotherapy using Latitude MRD testing Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and
3mo agoNTRANatera, Inc. Q2 2026 Earnings Conference Call - NATERA INCEarnings Call TranscriptsHello, everyone. Thank you for joining us and welcome to Natera's second quarter 2026 Earnings Conference call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a quest
3mo agoNTRANatera Reports Second Quarter 2026 Financial ResultsBusiness WireNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2026. Recent Financial Highlights Generated total
3mo agoNTRANatera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder CancerBusiness WireFollows Signatera’s recent U.S. FDA approval in MIBC and Japanese PMDA approval in CRC Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has submitted an
3mo agoNTRANatera to Report its Second Quarter Results on August 6, 2026Business WireNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2026, after the market closes on August 6, 2026.
3mo agoNTRASignatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology StudyBusiness WireSignatera outperformed AMERK, the current standard of care for prognosis and recurrence monitoring, across sensitivity, positive and negative predictive value, and lead time to recurrenceNatera, Inc. (NASDAQ:NTRA), a
3mo agoNTRAFinalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ PortfolioBusiness WireSurveillance coverage significantly strengthened with new LCD across kidney, heart, and lung transplantation, expanding coverage for Prospera testing across critical post-transplant settingsNatera, Inc. (NASDAQ:NTRA), a
4mo agoNTRANatera Announces IVDR Certification for Signatera™ Across Multiple CancersBusiness WireSignatera is the first personalized molecular residual disease (MRD) test for solid tumors to receive IVDR certification in the EU Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine,
4mo agoNTRASignatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal CancerBusiness WireNewly published study shows Signatera MRD-positive patients lived longer with adjuvant chemotherapy, while MRD-negative patients saw no significant benefit First predictive data for overall survival from GALAXY trial
4mo agoNTRANatera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck CancerBusiness WireSignatera™ will be used to evaluate molecular response to APG-157 in the neoadjuvant, induction, and adjuvant settingsNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Aveta
4mo agoNTRA ELDNNatera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant TrialBusiness WireProspera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026Natera, Inc.
4mo agoNTRASignatera™ Receives Regulatory Approval in Japan for Colorectal CancerBusiness WireFirst PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch expected by year-end, pending final reimbursement and pricing Natera,
4mo agoNTRANCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline UpdateBusiness WireNCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC)Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel
4mo agoNTRANatera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant CongressBusiness WireData, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organsNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced its
5mo agoNTRAGoldman Sachs 47th Annual Global Healthcare Conference - Natera IncEarnings Call TranscriptsAll right. Thank you. Well, good morning, everyone. I'm Evie Kozlowski of the Life Science Tools and Diagnostics Analyst here at Goldman Sachs, and I'm joined here today by Mike Brophy, CFO of Natera. Good morning. Thank
5mo agoCYDY NTRANatera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal CancerBusiness WireNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized
5mo agoNTRANatera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of DirectorsBusiness WireNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to the Company's board of directors. "Tom and Eric
5mo agoNTRANatera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory MelanomaBusiness WireSignatera™ to evaluate molecular response to investigational dendritic cell therapy as part of Diakonos' Phase I/II trial Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine,
5mo agoNTRANatera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast CancerBusiness WireSignatera™ will be used to identify patients who may be able to delay or defer adjuvant CDK4/6 inhibitor therapy in intermediate-risk HR+/HER2- breast cancer SIGNAL is a new group of Natera-sponsored
5mo agoNTRANatera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing TechnologyBusiness WireStudy provides prospective, clinically-validated performance data at challenging low fetal fraction levels, raising industry standard Reduces no-call rate to 0.5%, enabling results for more patients and closing a key
5mo agoNTRANatera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in OncologyBusiness WireOverall program, including 3 oral presentations, delivers unmatched evidence across the MRD landscape Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark
5mo agoNTRANatera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the WorldBusiness WireCompany to open second facility and new lab space to accommodate rapid growth Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced a significant expansion of its
5mo agoNTRAEXPAND Trial of Natera's Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients EnrolledBusiness WireMilestone follows prestigious oral plenary presentation of EXPAND data at SMFM Annual Meeting Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that
6mo agoNTRASignatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)Business WireMarks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions Solidifies Natera's Treatment on MRD (TOMR) approach as the new standard of care in MIBC, enabling
6mo agoNTRANatera, Inc. Q1 2026 Earnings Conference Call - Natera, Inc.Earnings Call TranscriptsLadies and gentlemen, welcome to Natera's first quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question-a
6mo agoNTRANatera Reports First Quarter 2026 Financial ResultsBusiness WireNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights Generated total
6mo agoNTRANatera to Report its First Quarter Results on May 7, 2026Business WireNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its first quarter ended March 31, 2026, after the market closes on May 7, 2026.
6mo agoNTRAProspera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLTBusiness WireBroad evidence, including six oral presentations, highlights Prospera's ability to enable earlier detection, refine risk stratification, and inform clinical decision-making in transplant care Natera, Inc.